Journal of Clinical Oncology Journal
Overview
Publication venue for
- A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naive patients with metastatic or unresectable high-grade gastroenteropanncreatic or lung neuroendocrine carcinoma. 38. 2020
- Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. 38. 2020
- Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.. 38. 2020
- Immune checkpoint inhibitor use in cancer patients with a pre-existing history of autoimmune disorders. 38. 2020
- PCR-based comprehensive genomic profiling (PCR-CGP): Feasibility from > 20,000 tumor tissue specimens (TTS) and predicted impact on actionable biomarker identification versus hybrid capture (H)CGP and plasma (P)-CGP.. 38. 2020
- Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.. 38. 2020
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. 38:1797. 2020
- A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.. 37. 2019
- A single-center retrospective analysis of the effect of Radium-223 (Xofigo) on pancytopenia in patients with metastatic castration-resistant prostate cancer.. 37. 2019
- DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.. 37. 2019
- DPP4 inhibitors as novel agents in improving survival in patients with prostate cancer: A SEER-Medicare study.. 37. 2019
- Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).. 37. 2019
- Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort (MCAEC).. 37. 2019
- No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment.. 37. 2019
- Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. 37:3300-3309. 2019
- Racial disparities in end-of-life care among Louisiana cancer decedents in a population-based study from 2011-2017.. 37. 2019
- Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.. 37. 2019
- Smoking history and PD-1/PDL-1 pathway blockade: Predicting response to treatment in metastatic cancer.. 37. 2019
- A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.. 36. 2018
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.. 36. 2018
- Evaluating the impact of African American ancestry among men with localized prostate cancer treated with radical prostatectomy.. 36. 2018
- Evaluation of a predefined AS threshold in a large cohort of men with localized prostate cancer.. 36. 2018
- Optimal cut points for Ki-67 proliferative index in predicting survival in high grade neuroendocrine tumors.. 36. 2018
- PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.. 36. 2018
- The role of Ki-67 in determining optimal chemotherapy in high grade neuroendocrine tumors.. 36. 2018
- Trans-intra-arterial gemcitabine versus continuation of IV gemcitabine and nab-paclitaxel following radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC).. 36. 2018
- Safety and efficacy of nab-paclitaxel (nab-P)-based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2.. 35. 2017
- Liver needle biopsies and prediction of histologic tumor grade for midgut neuroendocrine tumors.. 34. 2016
- Very late relapse metastatic renal cell carcinoma: Characteristics and outcomes of patients with a disease-free interval of greater than 10 years.. 34. 2016
- Adenosquamous carcinoma of the lung: a single institution experience in the era of molecular testing.. 33. 2015
- Effect of sex, weight, and body mass index on plasma lanreotide levels.. 33. 2015
- In vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.. 33. 2015
- In-vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.. 33. 2015
- Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: A single-institution experience.. 33. 2015
- Impact of absence of in-house radiation facilities for patients (pts) treated with concurrent chemoradiotherapy (CURT) for locally advanced head and cancer (LAHNC): A 3-year public hospital (PH) experience at Louisiana State University (LSU) in New Orleans.. 32. 2014
- Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Single-institution experience. 32. 2014
- Outcomes of patients (pts) with metastatic non-clear-cell renal cell carcinoma (nccRCC) treated with pazopanib. 32. 2014
- Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies.. 32. 2014
- Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. 32. 2014
- A single-center experience of modified FOLFOX-6 in locally advanced and metastatic pancreatic adenocarcinomas. 31. 2013
- Neuroendocrine tumors (NETs) of unknown primary: Is early surgical exploration and aggressive debulking justifiable?. 31. 2013
- Long-term outcome from RTOG 9517: A phase I/II study of accelerated partial breast irradiation (APBI) with mulitcatheter brachytherapy (MCT) following lumpectomy for early-stage breast cancer. 30. 2012
- Risk of adverse cardiovascular events (CVE) and incident diabetes mellitus (DM) in patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT): A meta-analysis of adjusted observational results. 30. 2012
- Thymidylate synthase expression and pemetrexed therapy in NSCLC. 29. 2011
- Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66. 28:853-858. 2010
- NSCLC in Louisiana: Thymidylate synthase and pemetrexed therapy. 28. 2010
- Differences in treatment and outcomes of non-small cell lung cancer (NSCLC) in Louisiana compared to the rest of the United States: A National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) analysis. 26. 2008
Identity
International Standard Serial Number (ISSN)
- 0732-183X